References
- Writing Group for the Women's Health Initia-tive Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal wo-men. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
- Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27
- Roy JA, Sawka CA, Pritchard KI. Hormone replacement therapy in women with breast cancer: do the risks outweigh the benefits? J Clin Oncol 1996;14:997–1006
- Rostom AY. The management of menopausal sequelae in patients with breast cancer. Clin Oncol 2001;13:174–80
- Beckman MW, Jap D, Djahansouzi S, et al. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symp-toms, bone mineral density and recurrence rates. Oncology 2001;60:199–206
- Eden JA, Bush T, Nand S, et al. A case-control study of combined continuous estrogen—proges-tin replacement therapy among women with personal history of breast cancer. Menopause 1995;2:67–72
- Eden JA, Wren BG. Hormone replacement therapy after breast cancer: a review. Cancer Treat Rev 1996;22:335–43
- Dew J, Eden J, Beller E, et al. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998;1:137–42
- Marsden J, Baum M, Sacks NPM. Hormone replacement therapy in women with previous breast cancer. Trends Endo crinol Metab 1998;9:32–8
- Vassilopolou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localised breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999;17: 1482–7
- Natrajan PK, Soumakis K, Gambrell RD. Estro-gen replacement therapy in women with previous breast cancer. Am J Obstet Gynecol 1999;181:288–95
- Natrajan PK, Puthugramam K, Gambrell RD. Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol 2002;187:289–95
- Urgis-Vrkaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999;25:146–51
- O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Nail Cancer Inst 2001;93:754–62
- Col NF, Hirota LK, Orr RK, et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357–63
- Peters GN, Fodera T, Sabol J, et al. Estrogen replacement therapy after breast cancer: a 12-year follow-up. Ann Surg Oncol 2001;8:828–32
- Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortal-ity. Med J Aust 2002;177:347–51
- De La Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039–43
- Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormonal replacement therapy in menopausal women: endometrial hypoplasia and irregular bleeding. Cochrane Database Syst Rev 2000;2:CD000402
- Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flushes in survivors of breast cancer: a randomised con-trolled trial. Lancet 2000;356:2059–63
- Norman SG, Studd JW. A survey of views on hormone replacement therapy. Br J Obstet Gynaecol 1994;101:879–87
- Dennerstein L, Shelley J, Smith AM, Ryan M. Hysterectomy experience among mid-aged Aus-tralian women. Med J Aust 1994;161:311–13
- Lee CG, McCormick B, Mazumdar M, et al. Infiltrating breast carcinoma in patients age 30 years and younger: long term outcome for life, relapse and second primary tumors. Int J Radiat Oncol Biol Phys 1992;23:969–75
- Durna EM, Crowe SM, Leader LR, et al. Quality of life of breast cancer survivors: the impact of hormonal replacement therapy. Climacteric 2002;5:266–76
- Vassilopoulou-Selin R, Zolinski C. Estrogen replacement therapy in women with breast cancer: a survey of patient attitudes. Am J Med Sci 1992;304:145–9
- Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J 1974;1:409–12
- Clemons M, Danson S, Howell A. Tamoxifen (`Nolvadex'): a review. Cancer Treat Rev 2002;28:165–80